• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

种族间出血风险的差异:一项比较韩国和英国人群的生态流行病学研究。

Racial Differences in Bleeding Risk: An Ecological Epidemiological Study Comparing Korea and United Kingdom Subjects.

机构信息

Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Division of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.

出版信息

Thromb Haemost. 2024 Sep;124(9):842-851. doi: 10.1055/a-2269-1123. Epub 2024 Feb 15.

DOI:10.1055/a-2269-1123
PMID:38359877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11349425/
Abstract

BACKGROUND

This study aimed to evaluate racial differences in bleeding incidence by conducting an ecological epidemiological study using data from Korea and the United Kingdom.

METHODS

We included healthy participants from the Korean National Health Insurance Service-Health Screening and the UK Biobank who underwent health examinations between 2006 and 2010 and had no comorbidities or history of medication use. Finally, 112,750 East Asians (50.7% men, mean age 52.6 years) and 210,995 Caucasians (44.7% men, mean age 55.0 years) were analyzed. The primary outcome was composed of intracranial hemorrhage (ICH) and bleeding from the gastrointestinal, respiratory, and genitourinary systems.

RESULTS

During the follow-up, primary outcome events occurred in 2,110 East Asians and in 6,515 Caucasians. East Asians had a 38% lower 5-year incidence rate compared with Caucasians (3.88 vs. 6.29 per 1,000 person-years; incidence rate ratio [IRR]: 0.62, 95% confidence interval [CI]: 0.59-0.65). East Asians showed a lower incidence of major bleeding (IRR: 0.86, 95% CI: 0.81-0.91), bleeding from the gastrointestinal (IRR: 0.53, 95% CI: 0.49-0.56), and genitourinary systems (IRR: 0.49, 95% CI: 0.44-0.53) compared with Caucasians. The incidence rates of ICH (IRR: 3.20, 95% CI: 2.67-3.84) and bleeding from the respiratory system (IRR: 1.28, 95% CI: 1.11-1.47) were higher in East Asians. Notably, East Asians consuming alcohol ≥3 times/week showed a higher incidence of the primary outcome than Caucasians (IRR: 1.12, 95% CI: 1.01-1.25).

CONCLUSION

This ecological study revealed significant racial differences in bleeding incidence, influenced by anatomical sites and lifestyle habits, underscoring the need for tailored approaches in bleeding management based on race.

摘要

背景

本研究旨在通过对来自韩国和英国的数据进行生态流行病学研究,评估出血发生率的种族差异。

方法

我们纳入了韩国国民健康保险服务-健康筛查和英国生物银行在 2006 年至 2010 年间接受健康检查且无合并症或用药史的健康参与者。最终,分析了 112750 名东亚人(50.7%为男性,平均年龄 52.6 岁)和 210995 名高加索人(44.7%为男性,平均年龄 55.0 岁)。主要结局由颅内出血(ICH)和胃肠道、呼吸道和泌尿生殖系统出血组成。

结果

在随访期间,东亚人有 2110 人发生主要结局事件,高加索人有 6515 人发生主要结局事件。东亚人的 5 年发生率比高加索人低 38%(每 1000 人年 3.88 与 6.29;发生率比[IRR]:0.62,95%置信区间[CI]:0.59-0.65)。东亚人发生主要出血(IRR:0.86,95%CI:0.81-0.91)、胃肠道出血(IRR:0.53,95%CI:0.49-0.56)和泌尿生殖系统出血(IRR:0.49,95%CI:0.44-0.53)的发生率均低于高加索人。ICH(IRR:3.20,95%CI:2.67-3.84)和呼吸道出血(IRR:1.28,95%CI:1.11-1.47)的发生率在东亚人更高。值得注意的是,每周饮酒≥3 次的东亚人主要结局的发生率高于高加索人(IRR:1.12,95%CI:1.01-1.25)。

结论

本生态研究揭示了出血发生率的显著种族差异,受解剖部位和生活方式习惯的影响,这凸显了基于种族制定出血管理个体化方法的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c76/11349425/962c58b27733/10-1055-a-2269-1123-i24010017-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c76/11349425/45ad6451433b/10-1055-a-2269-1123-i24010017-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c76/11349425/75861e96f628/10-1055-a-2269-1123-i24010017-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c76/11349425/962c58b27733/10-1055-a-2269-1123-i24010017-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c76/11349425/45ad6451433b/10-1055-a-2269-1123-i24010017-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c76/11349425/75861e96f628/10-1055-a-2269-1123-i24010017-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c76/11349425/962c58b27733/10-1055-a-2269-1123-i24010017-3.jpg

相似文献

1
Racial Differences in Bleeding Risk: An Ecological Epidemiological Study Comparing Korea and United Kingdom Subjects.种族间出血风险的差异:一项比较韩国和英国人群的生态流行病学研究。
Thromb Haemost. 2024 Sep;124(9):842-851. doi: 10.1055/a-2269-1123. Epub 2024 Feb 15.
2
Racial Differences in Ischemic and Hemorrhagic Stroke: An Ecological Epidemiological Study.种族差异与缺血性卒中和出血性卒中:一项生态流行病学研究。
Thromb Haemost. 2024 Sep;124(9):883-892. doi: 10.1055/a-2278-8769. Epub 2024 Feb 29.
3
Modifiable lifestyle factors and lifetime risk of atrial fibrillation: longitudinal data from the Korea NHIS-HealS and UK Biobank cohorts.可改变的生活方式因素与心房颤动终生风险:来自韩国 NHIS-HealS 和英国生物银行队列的纵向数据。
BMC Med. 2024 May 13;22(1):194. doi: 10.1186/s12916-024-03400-4.
4
Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.东亚人群别在别嘌醇相关严重皮肤不良反应的真实世界证据:基于人群的队列研究。
Clin Transl Sci. 2021 May;14(3):1002-1014. doi: 10.1111/cts.12964. Epub 2021 Jan 27.
5
Ethnic Differences in Thrombotic Profiles of Acute Coronary Syndrome Patients and Relationship to Cardiovascular Outcomes: A Comparison of East Asian and White subjects.急性冠状动脉综合征患者血栓形成特征的种族差异及其与心血管结局的关系:东亚人和白种人之间的比较。
Thromb Haemost. 2024 Jun;124(6):501-516. doi: 10.1055/s-0043-1777794. Epub 2023 Dec 29.
6
Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs.抗血小板治疗期间缺血/出血风险权衡的种族差异:来自 7 项 RCT 的个体患者水平里程碑荟萃分析。
Thromb Haemost. 2019 Jan;119(1):149-162. doi: 10.1055/s-0038-1676545. Epub 2018 Dec 31.
7
Evidence for reduced susceptibility to cardiac bradycardias in South Asians compared with Caucasians.与高加索人相比,南亚人对心脏心动过缓的敏感性降低。
Heart. 2018 Aug;104(16):1350-1355. doi: 10.1136/heartjnl-2017-312374. Epub 2018 Feb 20.
8
Clinical outcomes of adjusted-dose versus standard-dose prasugrel in East Asian patients with acute myocardial infarction.调整剂量普拉格雷与标准剂量普拉格雷在东亚急性心肌梗死患者中的临床结局。
Int J Cardiol. 2024 Sep 1;410:132197. doi: 10.1016/j.ijcard.2024.132197. Epub 2024 May 31.
9
Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians?东亚人群的抗栓治疗策略是否应与高加索人群有所不同?
Curr Vasc Pharmacol. 2018;16(5):459-476. doi: 10.2174/1570161116666180117103238.
10
Mortality in South Asians and Caucasians after percutaneous coronary intervention in the United Kingdom: an observational cohort study of 279,256 patients from the BCIS (British Cardiovascular Intervention Society) National Database.英国经皮冠状动脉介入治疗后南亚人和高加索人死亡率的观察队列研究:来自 BCIS(英国心血管介入学会)国家数据库的 279,256 名患者的观察队列研究。
JACC Cardiovasc Interv. 2014 Apr;7(4):362-71. doi: 10.1016/j.jcin.2013.11.013.

引用本文的文献

1
Trajectories of Lipid Profile Changes and Cardiovascular Outcomes in Elderly Asian Patients With Atrial Fibrillation.老年亚洲房颤患者血脂谱变化轨迹与心血管结局
J Arrhythm. 2025 Jul 28;41(4):e70151. doi: 10.1002/joa3.70151. eCollection 2025 Aug.
2
Temporal trends in ischemic stroke and female sex as a risk modifier in atrial fibrillation: insights from non-anticoagulated Asian patients in a nationwide cohort study.缺血性卒中的时间趋势以及女性作为心房颤动风险修饰因素的研究:来自全国队列研究中未接受抗凝治疗的亚洲患者的见解
Lancet Reg Health West Pac. 2025 Jul 4;60:101619. doi: 10.1016/j.lanwpc.2025.101619. eCollection 2025 Jul.
3

本文引用的文献

1
A nationwide cohort study on incidence and mortality associated with extracranial vascular malformations.一项关于与颅外血管畸形相关的发病率和死亡率的全国性队列研究。
Sci Rep. 2023 Aug 25;13(1):13950. doi: 10.1038/s41598-023-41278-z.
2
Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry.非维生素 K 拮抗剂口服抗凝药、华法林与 ABC 路径依从性对分层结局的影响:COOL-AF 登记研究的赢率分析。
Thromb Haemost. 2024 Jan;124(1):69-79. doi: 10.1055/s-0043-1772773. Epub 2023 Aug 25.
3
Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis.
The triglyceride-glucose index, a marker of insulin resistance, as a predictor of thrombotic risk in atrial fibrillation.
甘油三酯-葡萄糖指数,一种胰岛素抵抗标志物,作为心房颤动血栓形成风险的预测指标。
Cardiovasc Diabetol. 2025 Jul 10;24(1):281. doi: 10.1186/s12933-025-02809-2.
4
Adherence to the ABC (atrial fibrillation better care) pathway and risk of adverse outcomes in patients with chronic kidney disease: a report from the prospective APHRS-AF registry.慢性肾脏病患者遵循ABC(房颤更佳治疗)路径与不良结局风险:来自前瞻性APHRS-AF注册研究的报告
Lancet Reg Health West Pac. 2025 May 12;58:101570. doi: 10.1016/j.lanwpc.2025.101570. eCollection 2025 May.
5
Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III.≥80岁老年房颤患者口服抗凝治疗的长期临床结局:来自GLORIA-AF注册研究III期的报告
Age Ageing. 2025 May 31;54(6). doi: 10.1093/ageing/afaf139.
6
Effects of the ABC pathway on clinical outcomes in very elderly Chinese patients with atrial fibrillation. A report from the optimal thromboprophylaxis in elderly Chinese patients with atrial fibrillation (ChiOTEAF) registry.ABC途径对高龄中国房颤患者临床结局的影响。来自中国老年房颤患者最佳血栓预防(ChiOTEAF)注册研究的报告。
Intern Emerg Med. 2025 Apr 27. doi: 10.1007/s11739-025-03928-0.
7
Machine learning to identify phenotypic clusters of patients with atrial fibrillation.利用机器学习识别房颤患者的表型聚类。
Heart Rhythm O2. 2024 Dec 12;6(2):139-141. doi: 10.1016/j.hroo.2024.12.001. eCollection 2025 Feb.
8
An Updated Global Perspective of Atrial Fibrillation: Trends, Risk Factors, and Socioeconomic Disparities.心房颤动的最新全球视角:趋势、风险因素及社会经济差异
CJC Open. 2024 Dec 15;7(3):259-261. doi: 10.1016/j.cjco.2024.12.003. eCollection 2025 Mar.
9
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results.具有单剂量减量标准的房颤患者应用阿哌沙班的结果:ASPIRE研究1年结果
Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):403-411. doi: 10.1093/ehjcvp/pvaf018.
10
Strategies for the prevention of ischemic stroke in atrial fibrillation in East Asia: clinical features, changes and challenges.东亚地区心房颤动患者缺血性卒中的预防策略:临床特征、变化与挑战
Lancet Reg Health West Pac. 2025 Feb 15;56:101495. doi: 10.1016/j.lanwpc.2025.101495. eCollection 2025 Mar.
口服抗凝剂对合并多种药物治疗的心房颤动患者的影响:一项荟萃分析。
Thromb Haemost. 2025 Feb;125(2):166-177. doi: 10.1055/s-0043-1770724. Epub 2023 Jul 3.
4
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN.2020年和2040年全球结直肠癌负担:来自全球癌症负担(GLOBOCAN)的发病率和死亡率估计
Gut. 2023 Feb;72(2):338-344. doi: 10.1136/gutjnl-2022-327736. Epub 2022 Sep 8.
5
Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper.房颤和静脉血栓栓塞症出血风险评估与管理:欧洲和亚太专家共识文件的执行摘要。
Thromb Haemost. 2022 Oct;122(10):1625-1652. doi: 10.1055/s-0042-1750385. Epub 2022 Jul 6.
6
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.《日本循环学会/日本心律学会2020年心律失常药物治疗指南》
Circ J. 2022 Oct 25;86(11):1790-1924. doi: 10.1253/circj.CJ-20-1212. Epub 2022 Mar 11.
7
Racial and Ethnic Considerations in Patients With Atrial Fibrillation: JACC Focus Seminar 5/9.种族和民族因素在心房颤动患者中的考虑:JACC 焦点研讨会 5/9.
J Am Coll Cardiol. 2021 Dec 21;78(25):2563-2572. doi: 10.1016/j.jacc.2021.04.110.
8
2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.2021 年亚太心律学会心房颤动卒中预防聚焦更新共识指南:执行摘要。
Thromb Haemost. 2022 Jan;122(1):20-47. doi: 10.1055/s-0041-1739411. Epub 2021 Nov 13.
9
Accelerometer-derived physical activity and risk of atrial fibrillation.加速度计测量的身体活动与心房颤动风险。
Eur Heart J. 2021 Jul 1;42(25):2472-2483. doi: 10.1093/eurheartj/ehab250.
10
Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients.房颤患者遵循“房颤优化管理路径”:对 28.5 万名患者临床结局的影响——系统评价和荟萃分析。
Thromb Haemost. 2022 Mar;122(3):406-414. doi: 10.1055/a-1515-9630. Epub 2021 Jun 21.